Fresenius SE Quick Ratio 2016-2024 | FSNUY
Historical quick ratio values for Fresenius SE (FSNUY) over the last 10 years.
Fresenius SE Quick Ratio Historical Data |
Date |
Current Assets - Inventory |
Current Liabilities |
Quick Ratio |
2024-06-30 |
$10.00B |
$9.96B |
1.00 |
2024-03-31 |
$9.45B |
$9.09B |
1.04 |
2023-12-31 |
$10.83B |
$10.10B |
1.07 |
2023-09-30 |
$45.90B |
$31.77B |
1.45 |
2023-06-30 |
$15.58B |
$17.51B |
0.89 |
2023-03-31 |
$15.19B |
$17.09B |
0.89 |
2022-12-31 |
$14.17B |
$14.39B |
0.98 |
2022-09-30 |
$14.55B |
$14.97B |
0.97 |
2022-06-30 |
$15.03B |
$15.22B |
0.99 |
2022-03-31 |
$15.24B |
$0.39B |
39.25 |
2021-12-31 |
$15.67B |
$17.82B |
0.88 |
2021-09-30 |
$15.42B |
$18.10B |
0.85 |
2021-06-30 |
$15.31B |
$18.32B |
0.84 |
2021-03-31 |
$15.19B |
$19.23B |
0.79 |
2020-12-31 |
$13.51B |
$15.10B |
0.90 |
2020-09-30 |
$14.96B |
$16.20B |
0.92 |
2020-06-30 |
$14.45B |
$17.00B |
0.85 |
2020-03-31 |
$13.90B |
$17.64B |
0.79 |
2019-12-31 |
$13.03B |
$15.55B |
0.84 |
2019-09-30 |
$12.78B |
$15.32B |
0.83 |
2019-06-30 |
$12.65B |
$15.45B |
0.82 |
2019-03-31 |
$13.00B |
$15.53B |
0.84 |
2018-12-31 |
$13.67B |
$15.68B |
0.87 |
2018-09-30 |
$13.27B |
$15.46B |
0.86 |
2018-06-30 |
$13.37B |
$14.46B |
0.93 |
2018-03-31 |
$12.88B |
$13.83B |
0.93 |
2017-12-31 |
$10.57B |
$12.06B |
0.88 |
2017-09-30 |
$11.41B |
$12.51B |
0.91 |
2017-06-30 |
$10.56B |
$11.41B |
0.93 |
2017-03-31 |
$10.45B |
$10.85B |
0.96 |
2016-12-31 |
$9.53B |
$9.46B |
1.01 |
2016-09-30 |
$8.95B |
$9.35B |
0.96 |
2016-06-30 |
$9.05B |
$9.10B |
1.00 |
2016-03-31 |
$8.51B |
$8.16B |
1.04 |
2015-12-31 |
$8.95B |
$8.23B |
1.09 |
Sector |
Industry |
Market Cap |
Revenue |
Medical |
Medical - Outpatient & Home Care |
$19.704B |
$24.011B |
Fresenius SE & Co is a health care company. It offers products and services for dialysis, hospitals and outpatient treatment. The company's business segment consists of Fresenius Medical Care is engaged in treating with chronic kidney failure; Fresenius Helios is a hospital operator; Fresenius Kabi supplies essential drugs, clinical nutrition products, medical devices and services and Fresenius Vamed plans, develops and manages healthcare facilities. Fresenius SE & Co is headquartered in Bad Homburg, Germany.
|